Inogen (INGN) Receives Daily Coverage Optimism Rating of 0.10

Media stories about Inogen (NASDAQ:INGN) have been trending somewhat positive on Saturday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inogen earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 47.2867768802667 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Get Inogen alerts: Comparing Halyard Health (HYH) and Inogen (INGN) (americanbankingnews.com) ‘The stock market has sucked on nitrous oxide’ �� Wall… (beaumontenterprise.com) EPS Calculations to Consider �� Inogen Inc (NASDAQ: INGN) (stocksmarketcap.com) Inogen’s shares drop on short seller Citron’s tweet (reuters.com) Inogen Hit By Citron Report; Analyst Rebuttal Calls This ‘An Excellent Entry Point’ (msn.com)

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 1st. Leerink Swann restated an “outperform” rating and set a $170.00 price target (up from $150.00) on shares of Inogen in a research report on Tuesday, May 1st. ValuEngine upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research report on Tuesday, February 13th. Finally, BidaskClub upgraded Inogen from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the company. Inogen has an average rating of “Buy” and an average target price of $178.00.

Inogen opened at $174.33 on Friday, according to Marketbeat. Inogen has a 1 year low of $87.01 and a 1 year high of $189.76. The company has a market cap of $3.66 billion, a P/E ratio of 133.08, a P/E/G ratio of 4.37 and a beta of 1.01.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.19. Inogen had a return on equity of 14.81% and a net margin of 9.36%. The business had revenue of $79.05 million for the quarter, compared to analyst estimates of $63.86 million. During the same period last year, the company earned $0.27 EPS. Inogen’s revenue for the quarter was up 50.6% compared to the same quarter last year. analysts predict that Inogen will post 1.76 earnings per share for the current year.

In other Inogen news, Director Heath Lukatch sold 2,500 shares of the stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $119.15, for a total value of $297,875.00. Following the completion of the sale, the director now owns 2,500 shares in the company, valued at approximately $297,875. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Alison Bauerlein sold 15,911 shares of the stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $124.48, for a total value of $1,980,601.28. Following the completion of the sale, the executive vice president now owns 20,072 shares of the company’s stock, valued at approximately $2,498,562.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,956 shares of company stock valued at $5,724,846. Company insiders own 5.29% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.